Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 2, 2009, Pages 138-146

  Wang, Jhi Joung ^a   Liu, Kuo Sheng ^b   Sung, K C ^b   Tsai, Chia Yin ^c   Fang, Jia You ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Buprenorphine; Injection; Lipid nanoparticles; Nanostructured lipid carriers; Prodrug; Solid lipid nanoparticles

Indexed keywords

BUPRENORPHINE; LACTATE DEHYDROGENASE; LINSEED OIL; LIPID EMULSION; NANOPARTICLE; PALMITIC ACID ETHYL ESTER;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DELAYED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HEMOLYSIS; MALE; NANOPHARMACEUTICS; NEUTROPHIL; NONHUMAN; PAIN; PARTICLE SIZE; PHASE PARTITIONING; PRIORITY JOURNAL; RAT; SURFACE CHARGE; TAIL FLICK TEST; ZETA POTENTIAL;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; EMULSIONS; ESTERS; LIPIDS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OILS; PARTICLE SIZE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES;

EID: 68949178553     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.06.008     Document Type: Article

References (47)

1. Boothby L.A., and Doering P.L. Buprenorphine for the treatment of opioid dependence. Am. J. Health-Syst. Pharm. 64 (2007) 266-272
2. Boyum A., Lovhaug D., Tresland L., and Nordlie E.M. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34 (1991) 697-712
3. Bunjes H., Koch M.H.J., and Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci. 92 (2003) 1509-1520
4. Bunjes H., Westesen K., and Koch M.H.J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129 (1996) 159-173
5. Calcagnetti D.J., Fleetwood S.W., and Holtzman S.G. Pharmacological profile of the potentiation of opioid analgesia by restraint stress. Pharmacol. Biochem. Behav. 37 (1990) 193-199
6. Chen Y., Dalwadi G., and Benson H.A.E. Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 1 (2004) 361-376
7. Cury-Boaventura M.F., Gorjão R., de Lima T.M., Piva T.M., Peres C.M., Soriano F.G., and Curi R. Toxicity of a soybean oil emulsion on human lymphocytes and neutrophils. J. Parenter. Enteral. Nutr. 30 (2006) 115-123
8. Driscoll D.F. Lipid injectable emulsions: pharmacoepial and safety issues. Pharm. Res. 23 (2006) 1959-1969
9. Escher M., Daali Y., Chabert J., Hopfgartner G., Dayer P., and Desmeules J. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin. Ther. 29 (2007) 1620-1631
10. Esposito E., Fantin M., Marti M., Drechsler M., Paccamiccio L., Mariani P., Sivieri E., Lain F., Menegatti E., Morari M., and Cortesi R. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 25 (2008) 1521-1530
11. Ettmayer P., Amidon G.L., Clement B., and Testa B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47 (2004) 2393-2404
12. Fang J.Y., Fang C.L., Liu C.H., and Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70 (2008) 633-640
13. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., and Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm. 314 (2006) 83-89
14. Jenning V., Thünemann A.F., and Gohla S.H. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199 (2000) 167-177
15. Jores K., Haberland A., Wartewig S., Mäder K., and Mehnert W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm. Res. 22 (2005) 1887-1897
16. Jores K., Mehnert W., and Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. 20 (2003) 1274-1283
17. Kaur I.P., Bhandari R., Bhandari S., and Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127 (2008) 97-109
18. Kim B.D., Na K., and Choi H.K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur. J. Pharm. Sci. 24 (2005) 199-205
19. Kleppner S.R., Patel R., McDonough J., and Constantin L.C. In-vitro and in-vivo characterization of a buprenorphine delivery system. J. Pharm. Pharmacol. 58 (2006) 295-302
20. Kuo Y.C., and Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365 (2009) 206-213
21. Liu K.S., Lin C.N., Shieh J.P., Chu C.C., Kuei C.H., and Wang J.J. The novel depot of buprenorphine propionate has a long-acting effect on physical dependence on morphine. Drug Dev. Res. 67 (2006) 462-469
22. Liu A.C., Lin T.Y., Su L.W., and Fuh M.R. Online solid-phase extraction liquid chromatography-electrospray-tandem mass spectrometry analysis of buprenorphine and three metabolites in human urine. Talanta 75 (2008) 198-204
23. Liu K.S., Tzeng J.I., Chen Y.W., Huang K.L., Kuei C.H., and Wang J.J. Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. Anesth. Analg. 102 (2006) 1445-1451
24. Lombardi Borgia S., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Röder B., Kramer K.D., and Schäfer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 110 (2005) 151-163
25. Marcato P.D., and Durán N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol. 8 (2008) 2216-2229
26. Muguet V., Seiller M., Barratt G., Ozer O., Marty J.P., and Grossiord J.L. Formulation of shear rate sensitive multiple emulsions. J. Control. Release 70 (2001) 37-49
27. Müller R.H. Lipid nanoparticles: recent advances. Adv. Drug Deliv. Rev. 59 (2007) 522-530
28. Müller R.H., Radtake M., and Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 (2002) 121-128
29. ®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68 (2008) 535-544
30. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6 (2006) 173-182
31. Ohtani M. Basic pharmacology of buprenorphine. Eur. J. Pain Suppl. 1 (2007) 69-73
32. Park I., Kim D., Song J., In C.H., Jeong S.W., Lee S.H., Min B., Lee D., and Kim S.O. Buprederm™, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm. Res. 25 (2008) 1052-1062
33. Pavan B., Dalpiaz A., Ciliberti N., Biondi C., Manfredini S., and Vertuani S. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13 (2008) 1035-1065
34. Raffa R.B., and Ding Z. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 9 (2006) 145-152
35. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., and Savolainen J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008) 255-270
36. Roy S.D., Roos E., and Sharma K. Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci. 83 (1994) 126-130
37. Schubert M.A., Harms M., and Müller-Goymann C.C. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur. J. Pharm. Sci. 27 (2006) 226-236
38. Sigmon S.C., Moody D.E., Nuwayser E.S., and Bigelow G.E. An injection depot formulation of buprenorphine: extended biodelivery and effects. Addiction 101 (2006) 420-432
39. Stinchcomb A.L., Dua R., Paliwal A., Woodard R.W., and Flynn G.L. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 12 (1995) 1526-1529
40. 10-development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 67 (2007) 141-148
41. Venkateswarlu V., and Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95 (2004) 627-638
42. Vivek K., Reddy H., and Murthy R.S.R. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of danzapine-loaded solid lipid nanoparticles. AAPS Pharm. Sci. Tech. 8 (2007) 83 Article
43. Wang J.J., Ho S.T., Hu O.Y.P., and Chu K.M. An innovative cold tail-flick test: the cold ethanol tail-flick test. Anesth. Analg. 80 (1995) 102-107
44. Wang J.J., Sung K.C., Yeh C.H., and Fang J.Y. The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions. Int. J. Pharm. 353 (2008) 95-104
45. Wong H.L., Bendayan R., Rauth A.M., and Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93 (2004) 1993-2008
46. Zhang X., Pan W., Gan L., Zhu C., Gan Y., and Nie S. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. 56 (2008) 1645-1650
47. zur Mühlen A., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45 (1998) 149-155